Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMindBio Therapeutics Corp.

MindBio Therapeutics Corp.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.085 CAD 0.01 ( 6.25%)
Last update at 2026-11-11T19:44:00Z
VOLUME
103
Market Cap
4.79M

Momentum Score

…

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.09
Low
0.09
High
52 Week Price Range
0.01
Low
3.99
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public disclosures for MindBio Therapeutics Corp (MBIO.CN) are limited; the company is listed in Canada and identifies as a biotechnology firm focused on therapeutic development. It appears positioned in emerging neuropsychiatric and novel-therapy areas where growth may be driven by clinical data, regulatory progress and partnerships. Investors may consider potential program milestones and collaborations as long-term value drivers.

Main risk is limited disclosure and an early-stage therapeutic profile that creates high clinical and regulatory failure risk, funding/dilution needs and low liquidity.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.08
Dividend Yield
-
Revenue TTM
-0.63M
Revenue Per Share
-0.01
Gross Profit TTM
-0.63M
Debt / Equity
-
ROE
-
Net Debt
2.18M
ROCE
79.00%
Diluted EPS TTM
-3.56

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -2.81M -0.41M -4.29M -7.47M
Net income -2.81M -0.41M -4.29M -7.47M
Selling general administrative 1.90M 0.63M 3.22M 2.90M
Reconciled depreciation - - 0.00M 0.04M
Operating income -1.93M -0.06M -3.16M -5.58M
Interest expense 0.58M 0.35M 0.45M 0.18M
Tax provision 0.00M 0.00M 0.00M 0.00M
Net interest income -0.58M -0.35M -0.45M -0.18M
Total revenue 0.00M 0.00M 0.00M 0.00M
Total operating expenses 1.93M 0.06M 3.16M 5.58M
Total other income expense net -0.30M -0.00M -0.67M -1.71M
Net income from continuing ops -2.81M -0.41M -4.29M -7.47M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 0.12M 0.19M 0.67M 1.61M
Other current assets - - 0.28M 0.22M
Total liab 2.56M 5.60M 6.09M 5.84M
Total stockholder equity -2.38M -5.35M -5.36M -4.23M
Capital stock 10.68M 5.48M 5.37M 4.51M
Retained earnings -15.29M -12.49M -12.38M -8.74M
Cash 0.06M 0.14M 0.32M 1.31M
Total current liabilities 2.56M 5.29M 2.93M 1.19M
Net debt 2.18M 4.84M 4.65M 3.18M
Short long term debt 2.24M 4.98M 2.16M -
Total current assets 0.12M 0.19M 0.67M 1.61M
Short term investments - 0.00M 0.01M 0.03M
Long term debt - - 2.82M 4.50M
Accounts payable 0.19M 0.23M 0.57M 1.19M
Non current assets total 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - 0.00M -0.03M
Net borrowings -0.01M -0.01M -0.11M 6.38M
Total cash from financing activities 0.43M 0.27M 1.04M 5.59M
Net income -2.81M -0.41M -4.29M -7.47M
Change in cash -0.05M -0.18M -1.17M 0.83M
Begin period cash flow -0.02M -0.07M 1.31M 0.48M
End period cash flow 0.06M 0.14M 0.32M 1.31M
Total cash from operating activities -0.49M -0.38M -2.21M -4.72M
Issuance of capital stock 0.44M 0.00M 1.15M 0.00M
Dividends paid - - 0.00M -0.79M
Capital expenditures 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.60M -0.17M -0.29M 0.82M
Stock based compensation 0.84M 0.00M 1.40M 0.00M
Other non cash items 0.56M 0.18M 0.95M 1.93M
Free cash flow -0.49M -0.38M -2.21M -4.72M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MBIO
MindBio Therapeutics Corp.		 0.01
6.25%		 0.09 - - 6.89 - 14.50 88.30
DRUG
Bright Minds Biosciences Inc		 0.06
0.19%		 32.18 - - - 13.50 - -0.10
METX
ME Therapeutics Holdings Inc.		 -
-%		 1.05 - - - 72.00 - -
TELI
Telescope Innovations Corp.		 -
-%		 0.34 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -
-%		 0.31 - - - 89.80 - -9.99

Profile*

MindBio Therapeutics Corp.

MindBio Therapeutics Corp., together with its subsidiaries, engages in researching, developing, and testing psychedelic substances as a potential treatment for the management of various mental health conditions in Australasia. Its lead drug candidate is MB22001, a form of lysergic acid diethylamide in Phase 2A trials. The company also develops wearable devices to collect biometric data in mental health patients taking psychedelic medicines; and invests in research that forms the basis for developing novel and clinically proven treatments for debilitating health conditions, such as depression, anxiety, PTSD, and chronic pain. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.

1055 West Georgia Street, Vancouver, BC, Canada, V6E 4N7

https://www.mindbiotherapeutics.com

Name Title Year Born
Mr. Justin Adam Hanka Co Founder, CEO & Director 1974
Mr. John M. Dinan Chief Financial Officer 1958

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CJT
CAD 111.15
+12.71%
CLS
CAD 374.20
+8.33%
GRZ
CAD 4.90
+7.46%
CTC-A
CAD 218.05
+6.38%
FEC
CAD 7.42
+5.85%
TF
CAD 4.13
-19.65%
TLO
CAD 5.98
-15.06%
FSZ
CAD 2.45
-14.04%
XNDU
CAD 3.60
-8.86%
ITR
CAD 2.75
-8.50%

Equity Sectors*

  • Basic Materials

    -2.63%

  • Communication Services

    -0.79%

  • Consumer Cyclical

    +0.08%

  • Consumer Defensive

    -0.12%

  • Energy

    +0.52%

  • Financial Services

    -1.15%

  • Healthcare

    -1.74%

  • Industrials

    -0.64%

  • Real Estate

    -0.12%

  • Technology

    -0.51%

  • Utilities

    -0.02%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…